news
Ketamine eases bipolar depression in new RCT
A new randomized controlled trial (RCT) found IV ketamine significantly reduced depressive symptoms in people with treatment-resistant bipolar depression, compared to a placebo. The University of Toronto study with Diana K. Orsini, MSc, MPH, sheds light on its potential for a patient group often excluded from prior psychedelic research.
A new randomized controlled trial (RCT) found IV ketamine significantly reduced depressive symptoms in people with treatment-resistant bipolar depression, compared to a placebo. The University of Toronto study with Diana K. Orsini, MSc, MPH, sheds light on its potential for a patient group often excluded from prior psychedelic research.
The architecture take
I’ve heard the whispers about ketamine for a while now, mostly for unipolar depression, but this RCT really pushes the envelope for bipolar. Researchers gave IV ketamine to people with treatment-resistant bipolar depression and saw significant antidepressant effects. Historically, there's been a real hesitancy here, a worry about triggering mania or psychosis in this group. This study begins to chip away at that, suggesting it might be safe and effective under controlled conditions. It matters because bipolar depression is notoriously difficult to treat, and options are limited when standard meds don't work. For anyone tracking psychedelic medicine, this is big. It opens the door for more clinical exploration into how these compounds regulate mood and nervous system activity beyond just classic depression. I'm watching to see if this accelerates broader access.